Vutrisiran for treating hereditary transthyretin-related amyloidosis

2.1 Vutrisiran (Amvuttra, Alnylam) is indicated for the 'treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy'.

2.2 The dosage schedule is available in the summary of product characteristics for vutrisiran.

2.3 £95,862.36 per 0.5 ml solution for injection containing 25 mg of vutrisiran (excluding VAT; company submission). At the recommended dose of 25 mg administered subcutaneously every 3 months, the estimated annual cost per patient is £383,449.44.

2.4 The company has a commercial arrangement. This makes vutrisiran available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.